NCT01003483

Metformin Versus Orlistat in Obese Polycystic Ovary Syndrome (PCOS) Patients

Orlistat Administration Facilitates the Obesity Treatment Among Obese PCOS Women

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 80 (actual)
• Sponsor: Yazd Research & Clinical Center for Infertility · Academic / Other
• Sex: Female
• Age: 18 Years – 40 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to compare the influence of Orlistat and Metformin on obesity treatment in obese PCOS women.

Detailed description

In a randomized clinical trial study, 80 obese women with BMI≥30, oligomenorrhae, hirsutism and presence of \> 12 ovarian follicles (2-10mm diameter), were evaluated. In metformin group , metformin was administered for patients 1500 mg daily for three months. In orlistate group, patients used orlistat tablets (120 mg, 3 times a day) for three months. BMI, serum LH and FSH levels, serum triglyceride and cholesterol levels and also patients' ovulation was compared before and after treatment.

Conditions

• Obesity

Interventions

Type	Name	Description
DRUG	orlistat	Tablet,120mg,three times a day,three months

Timeline

• Start date: 2008-12-01
• Primary completion: 2009-08-01
• Completion: 2009-11-01
• First posted: 2009-10-28
• Last updated: 2021-04-01

Locations

1 site across 1 country: Iran